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Abstract:Chest pain is a common reason for presentation to the emergency department (ED). Absolute criteria for Acute 
Coronary Syndrome without ST elevation (NSTE-ACS) are lacking. An acute coronary syndrome (ACS) needs to be dis-
tinguished from a variety of other cardiac and non-cardiac diseases that may cause chest pain.  
For patients with confirmed ACS, several scoring methods can be applied in order to distinguish patients in the coronary 
care unit who may benefit most from therapies. The PURSUIT, TIMI, GRACE and FRISC risk scores are well validated 
with this respect. However, none of these risk scores has been used in the identification of an ACS in the emergency set-
ting. The vast majority of patients with chest pain due to causes other than ACS were not evaluated in these trials. An evi-
dence-based systematic stratification and policy for these patients does not currently exist. 
The more recently developed HEART score is specifically designed to stratify all chest pain patients in the ED. The 
HEART score was validated in a retrospective multicenter study and proved to be a strong predictor of event free survival 
on one hand and potentially life threatening cardiac events on the other hand. The HEART score facilitates risk stratifica-
tion of chest pain patients in the ED.  
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INTRODUCTION 
  Chest pain is one of the most common reasons for pa-
tients to present to the emergency department (ED). An acute 
coronary syndrome (ACS) needs to be distinguished from a 
variety of other cardiac and non cardiac diseases that may 
cause chest pain. In a number of cases, a diagnosis can be 
made quickly, in particular in case of ST-segment elevation 
acute myocardial infarction (STEMI). However, STEMI 
patients represent only a small percentage of all chest pain 
patients in this setting. A variety of other diseases may 
mimic ACS, such as pleural and pericardial irritations, gas-
tro-intestinal reflux, pulmonary embolism, hyperventilation, 
musculoskeletal pain and cholecystitis [1-3].  
  The challenge in the ED is not only to identify patients at 
the highest risk, but also to identify patients with non-urgent 
diseases or even the absence of disease. These patients may 
be discharged immediately with minimal testing or interven-
tion. Clearly, when treated as ACS, the latter will be prone to 
unnecessary risks of various treatments, including the side 
effects of medication or radiation. In addition, this causes the 
occupation of hospital beds through admission of such pa-
tients and associated increase in medical costs. With the 
population’s increasing age and advancing medical tech-
niques, healthcare costs are a critical issue in many countries. 
Awareness of these costs as well as treatment risks is neces-
sary before considering a certain strategy for the individual 
patient [2]. 
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  Regarding patients with ACS, the diagnosis is confirmed 
in the vast majority of cases where significant ECG changes 
such as STEMI and/or increased levels of myocardial mark-
ers in plasma are present. However, absence of such abnor-
malities doesn’t exclude ACS. Therefore, the diagnosis of 
ACS is felt to be difficult to exclude in the early stage of the 
diagnostic process. It is important to make the diagnosis 
quickly, as patients benefit significantly from early treatment 
[3]. With this perspective in mind and the possible life 
threatening character of ACS, guidelines for chest pain pa-
tients are mainly focussed on the identification of those pa-
tients at the highest risk of an ACS. High risk patients will 
benefit most from early aggressive therapies. With this ap-
proach, the current guidelines disregard the many chest pain 
patients with a wide selection of non-urgent diagnoses in 
whom admission is not necessary.  
Risk Scores 
  Several scoring methods are developed in order to distin-
guish patients in the ED or coronary care unit at the highest 
risk of an ACS or an adverse outcome, who may benefit 
most from aggressive therapies. 
PURSUIT 
  The PURSUIT score (2000) was developed in a multina-
tional randomized clinical trial (Platelet glycoprotein IIb/IIIa 
in Unstable angina: Receptor Suppression Using Integrilin 
(eptifibatide) Therapy), with 9,461 patients, comparing epti-
fibatide (Integrilin) to placebo in the management of Unsta-
ble Angina (UA) or NonST-elevation Myocardial Infarction 
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investigators identified seven risk predictors for death and 
myocardial infarction (MI) in patients with acute coronary 
syndromes. Five of these risk factors were then combined 
into a scoring system: higher age, sex, worst Canadian Car-
diovascular Society (CCS) class of angina, signs of heart 
failure and ST-segment depression on the index ECG. The 
investigators did not include tachycardia and low systolic 
blood pressure in the final risk score (Table I). Scoring each 
of the five elements results in a possible score ranging from 
1 to 18. The PURSUIT score predicts the risk of death or 
death/MI at 30 days after admission. According to the PUR-
SUIT score ACS patients are divided into low, intermediate 
and high risk patients, with suggested therapies of early 
discharge, “watchful waiting” and aggressive antiplatelet / 
early invasive strategies respectively. The c-statistic of the 
original study for predicting the primary endpoint was 0.84 
for death alone and 0.67 for the composite endpoint of 
death/MI.  







Male 1  Sex 
Female 0 
No angina/CCS I/II  0  Worst CCS class past 6 weeks 
CCS III/IV  2 
Signs of heart failure    2 
ST depression on ECG    1 
                                                                                    Total
TIMI 
  The TIMI risk score (2000) is derived from the Throm-
bolysis in Myocardial Infarction (TIMI)-11B trial, a multina-
tional, randomized clinical trial, comparing unfractionated 
heparin to enoxaparin, which included all patients with con-
firmed ACS [5]. Data from 1,957 patients enrolled in the 
unfractionated heparin group were used to identify twelve 
elements of typical ACS findings by use of multivariate 
regression analysis. Seven of these elements remained statis-
tically significant in a multivariate analysis. Together these 
seven elements compose the TIMI score for unstable an-
gina/NSTEMI: age > 65 years,  3 classical risk factors for 
coronary artery disease (CAD), known CAD, use of Aspirin 
in the past 7 days, severe angina in the past 24 hours, ele-
vated cardiac markers and ST-deviation   0.5 mm (Table II). 
Each of these elements can be assigned with 0 or 1 points, 
resulting in a score of 0-7. The TIMI score predicts the risk 
of all cause mortality, MI and severe recurrent ischemia 
requiring urgent revascularization within 14 days after ad-
mission as well as benefit of enoxaparin. Event rates   
Table II. Composition of the TIMI Score for Unstable Angina / 
Non-ST-segment Elevation Myocardial Infarction 
(NSTEMI) 
Historical
0 Age > 65 years 
1
0   3 risk factors for CAD 
1
0 Known CAD (stenosis   50%) 
1
0 ASA use in past 7 days 
1
Presentation
0 Recent (  24H) severe angina 
1
0  cardiac markers 
1
0 ST deviation   0.5 mm 
1
                                                                               Total
CAD = Coronary artery disease, ASA = Acetyl Salicylic Acid 
increased significantly with increasing TIMI-scores. Accord-
ing to the TIMI score patients are divided into low (score 0-
2), intermediate (score 3-4) and high (score 5-7) risk catego-
ries. The c-statistic of the TIMI score in the original trial was 
0.65. The TIMI score was validated internally and externally 
in the enoxaparin group of the TIMI 11B trial and in both 
groups of the ESSENCE trial [5]. This validation showed 
comparable results with a mean c-statistic of 0.63. In addi-
tion the TIMI score is validated in several other databases 
and was compared with other scoring systems [6-8]. In vari-
ous succeeding trials the TIMI risk score was applied in 
analyzing treatment efficacy in various ACS risk groups.  
GRACE 
  The GRACE score (2003) was developed in a multina-
tional registry of 11,389 ACS patients (Global Registry of 
Acute Coronary Events) [9,10]. Registration was performed 
prospectively and retrospectively. Patients who died within 
24 hour after admission were excluded. After data collection, 
by use of multivariate logistic regression analysis, the inves-
tigators identified eight independent risk factors for in-
hospital death and post-discharge death at 6 months. These 
risk factors were then combined into a scoring system, con-
sisting of hemodynamic, laboratory, ECG and patient spe-
cific findings: Killip class for congestive heart failure (CHF), 
systolic blood pressure at presentation (SBP), heart rate at 
presentation (HR), age, creatinine level, cardiac arrest at 
admission, ST-segment deviation on the index ECG and 4 Current Cardiology Reviews, 2011, Vol. 7, No. 1  Backus et al. 
elevated cardiac enzyme levels. Each element has its own 
scoring, resulting in a possible score ranging from 1 to 372 
(Table III).  
  Event rates increased significantly with increasing 
GRACE-scores, ranging from  0.2% to  52% chance of in-
hospital death. The investigators did not divide patients into 
different risk categories. However, the individual risk of in-
hospital death may be used for optimal triage and manage-
ment. 
  The c-statistic of the GRACE score in the original data-
base was 0.83. The GRACE score was directly validated in a 
subsequent cohort of 3,972 patients and in 12,142 patients 
enrolled in the Global Utilization of Streptokinase and Tis-
sue Plasminogen Activator for Occluded Coronary Arteries 
(GUSTO)-IIb trial [11]. This validation showed comparable 
results with c-statistic results of 0.84 and 0.79 respectively. 
The c-statistics were similar for patients with (0.83) and 
without (0.82) ST segment deviation, with (0.81) and with-
out (0.83) elevated cardiac markers and for patients younger 
than 65 years (0.78) or older than 65 years of age (0.82). 
  In addition, the GRACE score has been validated in sev-
eral other databases [9] and was compared with other scoring 
systems in various succeeding trials [6-8].  
FRISC 
  The FRISC score (2004) is based on the FRISC (Fast 
Revascularisation in Instability in Coronary disease) II trial 
[12]. A multicenter, randomized clinical trial, which in-
cluded patients with unstable coronary artery disease. By use 
of multivariate regression analysis data from 1,235 patients 
enrolled in the non-invasive cohort were used to identify 
seven parameters as independent predictors of death/MI in 
patients with unstable angina. Together these seven parame-
ters compose the FRISC score, consisting of age   70 years, 
male gender, diabetes, previous MI, ST-segment depression 
on admission, elevated levels of Troponin and elevated lev-
els of Interleukin 6 or CRP (Table IV). Each of these ele-
ments can be appreciated with 0 or 1 points, resulting in a 
score of 0-7. The c-statistic of the FRISC score for the pre-
diction of death was 0.77 and for death/MI 0.70. Using dif-
ferent age cut offs had only minimal effect on the accuracy. 
Use of CRP alone instead of CRP and Interleukin-6 de-
creased the c-statistics to 0.76 and 0.68 respectively. 
  Patients were categorized into low, intermediate and high 
risk, based on the FRISC scores of 0-2, 3-4 and 5-7. The 
FRISC score is the only risk score that focussed on the 
treatment effect of early invasive strategies in ACS. To 
evaluate this effect the developed risk score was also per-
formed on the invasive cohort with 1,222 patients. In the 
high risk group mortality reduced from 15.4 – 5.2%, while 
the composite endpoint of death and MI was reduced in both 
intermediate and high risk groups. Therefore, investigators 
recommended early invasive strategies for patients with a 
FRISC score   3.
HEART 
  Recently (2008), the HEART risk score was developed 
for chest pain patients presenting to the ED [13,14]. The 
composition of the HEART score was not based on multi-
variate regression analysis but on the decision making clini-
cal factors according to expert opinion. The HEART score is 
composed of five parameters of clinical judgement: History, 
ECG, Age, Risk factors and Troponin. By appreciating each 
of these five elements with 0, 1 or 2 each patient patients will 
receive a score of 0-10 (Table V).  
  The HEART score was consecutively validated in a sin-
gle center retrospective study in 122 patients [13] and a   
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Table  IV. Composition of the FRISC Risk Score for 
Unstable Angina
0 Age  70 years 
1




0 Previous MI 
1
0 ST depression on ECG 
1
0 Elevated Troponin levels 
1
0 Elevated Interleukin 6 or CRP 
1
                                                         Total
multicenter retrospective investigation in 880 patients [14]. 
These studies were conducted in all patients presenting to the 
ED for chest pain within the first quarter of 2006. No other 
inclusion or exclusion criteria were used. The investigators 
calculated the predictive value of the HEART score for the 
combined endpoint of MI, Percutaneous Coronary Interven-
tion (PCI), Coronary Artery Bypass Grafting (CABG) or 
death within 6 weeks after presentation.  
  Event rates increased significantly with increasing 
HEART scores. The c-statistic was 0.90, indicating good to 
excellent discriminative power. The HEART score divides 
patients into low (0-3), intermediate (4-6) or high risk groups 
(7-10), with mean risks of an event of 0.9%, 12% and 65%, 
respectively. Consequently, an evidence-based decision may 
be made to discharge the patient from the ED or to admit for 
clinical observation or immediate aggressive therapies.  
  In addition, the HEART score is currently being vali-
dated in a multicenter prospective study in 2440 patients at 
10 hospitals. Follow up will be finalised by the end of the 
year 2010.  
Clinical Practice 
  Chest pain patients in the ED create uncertainty for all 
treating physicians. The decision to discharge a patient 
where ACS cannot be excluded may result in a serious life-
threatening outcome, while on the other hand, admission in 
case of atypical chest pain can lead to unnecessary medical 
treatment and costs. Risk score models may help the physi-
cian in making a timely decision in the emergency setting. In 
clinical practice, simple risk scores may be favourable, in 
particular when they can be calculated at the patient’s bed-
side. 
  For several years, researchers tried to develop a risk score 
for chest pain patients. Most of these risk scores have turned 
out to be difficult to use, require the use of a computer and, 
more importantly, are only validated for a selected group of 
patients such as STEMI or non-STEMI patients in the coro-
nary care unit. The main purpose of all these risk scores was 
not to make a diagnosis, but to identify the subset of high 
risk ACS patients who are likely to benefit most from ag-
gressive therapies.  
  For NSTE-ACS, several risk scores have been developed 
and validated in large patient populations. Most useful are 
the PURSUIT [4], TIMI [5] and [6] GRACE [9,10] risk 
scores, which were compared by De Araújo Gonçalves6 and 
Yan [7]. Despite the firm scientific basis for all three scoring 
systems and the recommendations in the guidelines, none is 
widely applied in clinical practice.  
  There is a clear difference in approach to patients admit-
ted at the coronary care unit and patients presenting to the 
ED with suspected ACS. In “real life”, as experienced by 
every physician, the whole range of chest pain patients pre-
senting to the ED runs from atypical chest pain to acute 
myocardial infarction. Therefore, the ideal risk score is ca-
pable of identifying patients at both ends of the spectrum.
Applicability Per Score 
  The PURSUIT study was conducted before the general 
introduction of the troponin assay. This crucial test, which is 
now generally applied, was not included in the PURSUIT 
score. This is one of the reasons why the score has not found 
its place in routine clinical practice. Another objection is that 
the PURSUIT score is determined for more than 50% by the 
age of the patient. Not surprisingly, higher ages of patients 
accompany higher mortality rates. This knowledge does not 
help the clinician to make better decisions in the emergency 
setting. The PURSUIT score has good predictive power for 
death alone (c-statistic 0.84), but rather poor predictive 
power for the combined endpoint of death/MI (c-statistic 
0.67). 
  The c-statistic of the TIMI score is 0.65 for the combined 
endpoint, indicating poor predictive power, but its simplicity 
makes it more useful than other scores. Even though the 
TIMI score is simple to calculate, it allows only binary 
choices, thereby ignoring the fact that many variables have 
“grey levels”. 
  The GRACE risk score has a good discriminative power 
with a c-statistic of 0.83. However, the complexity of the 
system requires special calculating tools to estimate risk at 
the bedside. Like the PURSUIT score, the GRACE score is 
determined to a large extent by the age of the patient, an 
element that holds only indirect evidence of coronary artery 
disease. Unfortunately, the GRACE investigators do not 
divide patients into different risk groups, making it less easy 
for the physician to interpret a patient’s individual score. 
  The FRISC score is quite comparable to the TIMI score, 
with a c-statistic of 0.70 for the combined endpoint, indicat-
ing only moderate discriminative power. The FRISC score is 
simple to calculate, but again allows only binary choices. 6 Current Cardiology Reviews, 2011, Vol. 7, No. 1  Backus et al. 
  Furthermore, none of the scores emphasizes the value of 
patient history, despite the fact that clinicians rely heavily on 
this aspect. The clinical judgement of the treating physician 
will already divide patients into low, intermediate and high 
risk groups for an adverse event. Without doubt, clinicians 
have developed strong competence in patient selection, not 
requiring complex algorithms and computer based calculat-
ing tools. Therefore, the ideal risk score closely follows this 
clinical reasoning. Based on general impression, patient 
history, ECG characteristics, risk factors for coronary athero-
sclerosis and levels of cardiac markers, a quick estimation 
can be made of the individual patient’s risk.  
Newly Developed Risk Score 
  The HEART risk score was specifically developed for 
chest pain patients presenting to the ED. The HEART score 
encloses each of the previous mentioned parameters of clini-
cal judgement: History, ECG, Age, Risk factors and Tro-
ponin levels. The HEART score translates the clinical 
judgement into a uniformly comprehensive number of 0-10. 
  Using the HEART score as guidance in the treatment of 
chest pain patients will clearly result in benefits for patients 
on both sides of the spectrum. The risk of MACE in patients 
with a HEART score  3 is 0.9%, 12% in patients with 
HEART score 4-6 and 65% in patients with a HEART score 
  7 (Fig. 1) [14].  
  Well known markers of increased risk, such as higher 
age, presence of risk factors and history of coronary   
Fig. (1). Probability of reaching a MACE in each HEART category 
[14]. 
atherosclerosis, are all incorporated in the HEART score. 
The combination of the five elements will allow for a more 
firmly based decision, mainly in cases of atypical presenta-
tion or absence of ECG abnormalities.  
  Compared with other risk scores, the HEART score is 
superior in terms of both simplicity and predictive power, 
not only for patients at high risk but also those patients at 
low risk for ACS (Table VI). Therefore it is quite useful for 
bedside clinical practice. 
Table V.  Composition of the HEART Score for Chest Pain Patients in the Emergency Department. 
HEART Score for Chest Pain Patients 
Highly suspicious  2 
Moderately suspicious  1 
History
Slightly suspicious   0 
Significant ST-depression   2
Non specific repolarisation disturbance   1
ECG
Normal  0
  65 year   2 
45 – 65 year   1
Age
  45 year   0 
  3 risk factors or history of atherosclerotic disease   2 
1 or 2 risk factors  1
Risk factors
No risk factors known  0 
  3x normal limit  2 
1-3x normal limit   1 
Troponin
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CONCLUSION 
  Previously developed risk scores for chest pain patients 
are designed to identify the subgroup of ACS patients in the 
CCU who are at the highest risk of an adverse event. Most of 
the described risk scores were developed after identification 
of those risk factors which were independently associated 
with the primary endpoint, usually death and/or MI. Statisti-
cally, these scores have a firm basis. However, the selection 
of parameters and their individual weighting make them less 
applicable in the bedside setting. The recently developed 
HEART score for chest pain patients in the ED closely fol-
lows clinical reasoning. Therefore, it is far more applicable 
to the whole range of chest pain in the emergency setting. 
The HEART score appears a strong predictor of event free 
survival on one hand and potentially life threatening cardiac 
events on the other hand. A direct comparison of the various 
risk scores within one clinical study is desirable.  
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